| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 127.7 | 110.3 |
| Profit before tax | -0.6 | -0.9 |
| Net income | -0.7 | -1.0 |
| EPS (diluted, $ a share) | $0.00 | $0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +15.7% |
|---|---|
| Operating margin | 3.2% |
10-Q filed with the SEC, NASDAQ: ARDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ardelyx, Inc.: key numbers
- Share price
- $3.07Close, Nov 16
- Market cap
- $772M
- Shares outstanding
- 251.37MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ardelyx, Inc.
All →Ardelyx Financial Results
Ardelyx reported Q3 2026 total product revenue of $125.5 million, a 19% increase year-over-year, driven primarily by $96.3 million in IBSRELA sales. The company reiterated its full-year 2026 revenue guidance for IBSRELA ($350M-$370M) and XPHOZAH ($110M-$120M) while maintaining a strong cash position of $285.3 million.
- Term
- Q3 2026
“Our third quarter results reflect the strength of the foundation we’ve built. IBSRELA year-over-year growth of 23% is the engine driving total product revenue of over $125 million for the quarter. With our robust tenapanor intellectual property portfolio, and our fully enrolled Phase 3 ACCEL trial for CIC, the value of IBSRELA continues to strengthen. Finally, with over $285 million in cash and investments, and a disciplined capital allocation strategy, we are well positioned to create and deliver significant long-term value.”
Mike Raab, President and Chief Executive Officer